As the inhibitory effect on TRAIL sensitivity was present in nearly half of the tumor cell lines with wildtype p53 status, we chose the ALL xenograft setting to further study the relevance of wildtype p53 for inhibition of extrinsic cell death as they rarely contain p53 mutations [19,20]. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.